Latest news with #GRN
India Today
24-06-2025
- Sport
- India Today
Neeraj Chopra enters Ostrava Golden Spike as favourite ahead of homecoming
After securing his first win of the season with a fantastic performance at the Paris Diamond League, Neeraj Chopra now shifts his focus to the Ostrava Golden Spike 2025 - a World Athletics Continental Tour (Gold level) meeting - scheduled for Tuesday, June 24. With the 90m barrier finally breached and a title already in his bag, this will be Neeraj's final competition before he returns home to Bengaluru for the inaugural Neeraj Chopra Classic on July will be Neeraj's first appearance at the Golden Spike event, having missed out in recent years due to injury. But this time, the 27-year-old arrives with momentum on his side, enjoying a strong run of form under the guidance of Jan Zelezny. It will be his fifth outing of the season, following impressive performances at the Diamond League meets in Doha and his own admission, Neeraj's primary goal this season is the World Championships in Tokyo, where he will enter as the defending champion. However, a strong showing in Ostrava would serve as ideal preparation for the championship in Japan later this year, while also underlining the progress he has made under Zelezny's mentorship. "I am really happy to work with such a great athlete and coach. I've already thrown 90m this year after a little bit more improvement in technique. So, let's see when it comes next time, but I am ready," said we've done a good training in Nymburk so I'll do my best here in Ostrava.""Main goal for the season is obviously, the World Championships in Tokyo."Neeraj was a guest at the event last year and now has the chance to impress everyone with his skills."When I was kid, I watched a lot of videos and photos of athletes like Usain Bolt competing here (at Ostrava Golden Spike). I came last year, but I didn't compete because of injury. Now I feel good, but I don't want to put any pressure on myself for 90m. But I'll try really hard," Neeraj field may not pose a major challenge for the Indian ace, but it still features stellar names like Anderson Peters and Thomas Rhler. Notably, Julian Weber—who has developed a strong rivalry with Neeraj this season—will be missing from the all eyes on him, Neeraj will look to secure the top spot on the podium before heading home for the inaugural NC Classic, where he will host some of the sport's biggest names in Bengaluru next Golden Spike 2025: Javelin throw entry listNeeraj Chopra - IND (PB - 90.23m)Jan Vyska - CZE (PB - 75.23m)advertisementMarc Anthony Minichiello - USA (PB - 82.65m)Alexandr Caca - CZE (PB - 78.44m)Douw Smit - RSA (PB - 83.29m)Martin Konecny - CZE (PB - 80.06m)Toni Keranen - FIN (PB - 85.27m)Thomas Rohler - GER (PB - 93.90m)Anderson Peters - GRN (PB - 93.07m)When will Neeraj Chopra be in action at the 64th Ostrava Golden Spike?Neeraj's event, the men's javelin throw, at the 64th Ostrava Golden Spike will begin at 10:30PM IST on June 24 (7PM local time).When and where to watch Neeraj Chopra at Ostrava Golden Spike 2025?In India, the event will be streamed live on the World Athletics' Inside Track. There will be no television broadcast of the event.- EndsMust Watch
Business Wire
15-05-2025
- Health
- Business Wire
AviadoBio Announces ASPIRE-FTD Phase 1/2 Clinical Trial in the UK at Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, and University College London
LONDON--(BUSINESS WIRE)--AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open in the UK. The trial is evaluating AVB-101, an investigational gene therapy, in people with frontotemporal dementia (FTD) with GRN gene mutations (FTD-GRN). Cambridge University Hospitals NHS Foundation Trust (CUH), which hosts an internationally renowned center of excellence in providing support and care for families affected by FTD, is now recruiting patients. University College London (UCL) is also expected to open for patient recruitment shortly. The Advanced Neurotherapies Centre at Cardiff and Vale University Health Board, one of the first surgical centers in Europe currently able to perform MRI-guided infusions of gene therapies, will provide the capability to dose clinical trial participants from the UK and beyond in the ASPIRE-FTD study. FTD is a devastating form of early-onset dementia that varies in each individual. Symptoms of FTD can include changes in personality or uncharacteristic behaviors, progressive loss of language, loss of executive function and cognitive abilities, apathy, and reduced mobility. 1-3 People with FTD who have disease-causing GRN mutations produce a reduced amount of progranulin protein. AVB-101 is an investigational one-time therapy designed to deliver a functional copy of the GRN gene directly to the brain, thereby potentially restoring progranulin levels and stopping disease progression in patients with FTD-GRN. 'Launching ASPIRE-FTD and treating our first patients with AVB-101 have been significant milestones in FTD-GRN research and gene therapy development,' said David Cooper, M.D., Chief Medical Officer of AviadoBio. 'AviadoBio was built on pioneering research from King's College London and the UK Dementia Research Institute. The opening of our UK clinical trial sites reflects this strong research heritage, and we're proud to bring this clinical trial to the UK to make it more accessible to people living with familial FTD in the region.' 'We are delighted to be able to surgically deliver AVB-101 in the ASPIRE-FTD trial in Cardiff, offering hope to patients living with FTD in the UK and beyond. The Advanced Neurotherapies Centre is funded by Health and Care Research Wales and is currently the only center in the UK, and one of two European centers, conducting these groundbreaking first in human clinical trials, delivering advanced gene and cell therapies directly to the brain for neurodegenerative diseases. This trial represents a major step forward in the search for a treatment in FTD, potentially bringing a new therapy to reality for patients,' commented Professor William Gray, Local PI and Neurosurgeon at Cardiff University and Cardiff and Vale University Health Board. 'The potential to halt FTD-GRN with a single procedure could be truly transformative for patients and their families,' said Professor James Rowe, Consultant Neurologist at Addenbrooke's Hospital and Professor of Cognitive Neurology at the Cambridge Centre for Frontotemporal Dementia. 'Combining excellence in clinical care with cutting-edge research is vital to driving progress in this extremely challenging field. Through studies like this we hope to one day be able to provide a potential cure for FTD.' 'UCL is a leader in the Genetic Frontotemporal dementia Initiative, a group of research centers across Europe and Canada with expertise in familial frontotemporal dementia. We are proud to be included in this groundbreaking trial where targeted delivery of a single low dose of AAV gene therapy to the thalamus could be potentially disease-modifying for FTD,' said Jonathan Rohrer, Professor of Neurology at the UCL Dementia Research Centre. AVB-101 is delivered as a one-time-only treatment using a minimally invasive stereotactic neurosurgical procedure directly to the part of the brain called the thalamus. The thalamus is a key hub for connectivity in the brain with widespread projections across the brain including the cortex – a key area affected in FTD-GRN. The neurosurgery procedure to deliver AVB-101 bypasses the blood-brain barrier, thereby limiting it to only the brain itself, where it is needed the most. At the same time, this potentially reduces the amount of dose required and systemic exposure in other parts of the body. More information about the ASPIRE-FTD study can be found at About ASPIRE-FTD ASPIRE-FTD is a Phase 1/2 open-label, multi-center study designed to evaluate the safety and preliminary efficacy of AVB-101 in patients with FTD-GRN. In the study, eligible patients receive a one-time administration of AVB-101 delivered as a set of MRI-guided infusions into the thalamus during a minimally invasive stereotactic neurosurgical procedure at an expert neurosurgical center in the US, UK, or EU. More information about the ASPIRE-FTD study can be found at or About AviadoBio At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with neurological conditions. With our deep understanding of the brain and suite of proprietary gene therapy platforms and delivery technologies, AviadoBio is working to overcome the challenges of delivering the right drug to the right place. Its innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. AviadoBio was founded on pioneering research from King's College London and the UK Dementia Research Institute and has a leadership team with extensive gene therapy development, delivery, and commercialization experience which uniquely positions the company for success in bringing transformative medicines to patients. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc., SV Health Investor's Dementia Discovery Fund (DDF), Advent Life Sciences, EQT Life Sciences (Dementia Fund), LifeArc Ventures, and Astellas Pharma. For more information, please visit and follow us on X @AviadoBio and LinkedIn at AviadoBio. References: Pressman PS and Miller BL. Biol Psychiatry 2014;75:574–81; Young JJ et al. Ther Adv Psychopharmacol 2018;8:33–48; Hogan DB et al. Can J Neurol Sci 2016;43 Suppl 1:S96–109. Notes to editors: The Advanced Neurotherapies Centre, formerly known as the BRAIN Unit, is funded by the Welsh Government through Health and Care Research Wales. About GENFI The Genetic Frontotemporal dementia Initiative (GENFI) is a group of research centers across Europe and Canada with expertise in familial frontotemporal dementia (FTD) and is coordinated by Professor Jonathan Rohrer at University College London. GENFI collaborates closely with other similar studies around the world through the FTD Prevention Initiative, which is helping to design clinical trials for genetic FTD.
The Hindu
26-04-2025
- Sport
- The Hindu
Neeraj Chopra Classic 2025: Meet the International Javelin Throw Stars Competing in India
The Neeraj Chopra classic will be held at the Sree Kanteerava stadium, Bengaluru on May 24. Tokyo 2020 gold medallist and reigning world champion Neeraj will headline the meet in his honour, but he'll face tough competition from some of the biggest names in javelin. Below is the list of international stars who will be in action. Neeraj Chopra Classic 2025 International Competitors Anderson Peters (GRN) Thomas Rohler (GER) Julius Yego (KEN) Curtis Thompson (USA) Genki Dean (JPN) Luiz Mauricio da Silva (BRA) Rumesh Pathirage (SRI)
Yahoo
07-03-2025
- Politics
- Yahoo
Okefenokee mining protection bills do not advance House
ATLANTA (WSAV) — Two bills proposed to protect the Okefenokee National Wildlife Refuge from mining did not advance through the House Thursday. The bills were aimed at Alabama-based Twin Pines Minerals' plan to strip mine for titanium dioxide, staurolite and zircon around three miles from the Okefenokee National Wildlife Refuge's Trail Ridge. The Trail Ridge is 'the ancient sand dune that serves as an earthen dam for the swamp,' GRN said, and is essential for hydrology in the Okefenokee and surrounding areas like the St. Mary River. House Bill 561 would have prohibited future mining along the Okefenokee's Trail Ridge, a GRN spokesperson said. If passed, it would've prohibited the director of the EPD 'from issuing, modifying, or renewing any permit or accepting any bond to conduct surface mining operations on Trail Ridge for future permit applications and amendments,' the bill said. The second bill, HB 562, would've place a five-year moratorium, or hold, on mining along the Okefenokee's Trail Ridge. GRN said that this hold would've provide state regulators and independent scientists time to evaluate how mining at the Twin Pines site could impact groundwater levels under and near the swamp. The five-year timeline would've aligned with the Twin Pines demo mine duration, which includes four years of active mining plus one year groundwater recovery monitoring. The Okefenokee mining bills were sponsored by several Republicans in Georgia's coastal areas, including Thomasville's Darlene Taylor, Savannah's Ron Stephens and St. Mary's Rep. Steven Sainz. Gerald Greene (R) of Cuthbert, Debbie Buckner (D) of Junction City and Carolyn Hugley (D) of Columbus also sponsored the bills. Proposals that didn't pass Thursday could still be brought up again later, but it can be more difficult to advance them. They could also be considered next year since this 2025 is the first year of a two-year session. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
21-02-2025
- Politics
- Yahoo
2 House bills introduced to protect Okefenokee
ATLANTA (WSAV) — Two bills were introduced to the Georgia House Thursday with intentions of protecting the Okefenokee National Wildlife Refuge from mining. The bills are aimed at Alabama-based Twin Pines Minerals' plan to strip mine for titanium dioxide, staurolite and zircon around three miles from the Okefenokee National Wildlife Refuge's Trail Ridge. The Trail Ridge is 'the ancient sand dune that serves as an earthen dam for the swamp,' GRN said, and is essential for hydrology in the Okefenokee and surrounding areas like the St. Mary River. The mining project has been hotly contested since they started seeking permits from the Georgia Environmental Protection Division (EPD) in 2019. House Bill 561 would prohibit future mining along the Okefenokee's Trail Ridge, a GRN spokesperson said. If passed, it would prohibit the director of the EPD 'from issuing, modifying, or renewing any permit or accepting any bond to conduct surface mining operations on Trail Ridge for future permit applications and amendments,' the bill said. The second bill, HB 562, would place a five-year moratorium, or hold, on mining along the Okefenokee's Trail Ridge. GRN said that this hold would provide state regulators and independent scientists time to evaluate how mining at the Twin Pines site could impact groundwater levels under and near the swamp. The five-year timeline would align with the Twin Pines demo mine duration, which includes four years of active mining plus one year groundwater recovery monitoring. HB 562 would pause the acceptance of applications for new permits and the acceptance of requests to modify existing permits by the EPD to expand the area of land affected by surface mining operations on Trail Ridge. These bills would allow mining on their nearly demonstration area with a state permit, GRN said, but they would not be able to mine across the rest of their site. The bills would also potentially allow for portions of land, and possible mining rights, to be purchased. This is a similar move to what U.S. Fish and Wildlife Service (FWS) did when they made the final decision to expand the acquisition boundary of the Okefenokee National Wildlife Refuge by approximately 22,000 acres. The expansion does not immediately add the land to the Refuge, but it would allow the Service to work with willing landowners to acquire lands through fee title or conservation easements. 'Both of these bills provide the opportunity for all the legislators and leadership to respond to their constituents to save the Okefenokee National Wildlife Refuge from mining that would harm the swamp and swamp tourism upon which the economies of the local communities depend,' said Rena Ann Peck, executive director of Georgia Rivers. In last year's session, another bill was introduced to place a three-year hold and passed the House but did not receive a floor vote by the Senate. Previous legislation has also been introduced like The Okefenokee Protection Act, but it did not make it through the legislative process. The Okefenokee mining bills are sponsored by several Republicans in Georgia's coastal areas, including Thomasville's Darlene Taylor, Savannah's Ron Stephens and St. Mary's Rep. Steven Sainz. Gerald Greene (R) of Cuthbert, Debbie Buckner (D) of Junction City and Carolyn Hugley (D) of Columbus also sponsored the bills. You can read HB 561 here: Georgia-2025-HB561-IntroducedDownload You can read HB 562 here: Georgia-2025-HB562-IntroducedDownload Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
